期刊
HEPATOLOGY RESEARCH
卷 45, 期 8, 页码 872-879出版社
WILEY
DOI: 10.1111/hepr.12427
关键词
hepatitis B surface antigen seroclearance; hepatitis B virus DNA; hepatocellular carcinoma; liver cirrhosis; nucleoside; nucleotide analog therapy; risk factors
资金
- Ministry of Health Labor and Welfare of Japan
AimSome patients develop hepatocellular carcinoma (HCC) during nucleoside/nucleotide analog (NA) therapy even if alanine aminotransferase (ALT) or hepatitis B virus (HBV) DNA levels are sufficiently reduced. The aim of this study is to identify the risk factors of development of HCC during NA therapy. MethodsSix hundred and two patients were analyzed who were continuously receiving NA for chronic HBV infection. The patients who developed HCC previously or within 1year of therapy were excluded. In the patients studied, the median duration of therapy was 90months. A total of 492 patients had chronic hepatitis (CH) and 110 had liver cirrhosis (LC). ResultsIn 602 patients, the rate of normalization of ALT, loss of serum HBV DNA and development of HCC were 90.4%, 55.4%, and 6.1%, respectively. The significant risk factors of development of HCC were LC status and duration of therapy. The annual incidence of HCC in LC patients was 2.53%/year, compared with 0.34%/year in CH patients. When the relation between the incidence of HCC and the response to therapy was evaluated, in patients with normalization of ALT level, loss of HBV DNA by real-time polymerase chain reaction or hepatitis B e-antigen seroconversion, the incidences of HCC was reduced to some extent. However, none of the patients who achieved hepatitis B surface antigen (HBsAg) seroclearance during NA therapy developed HCC. ConclusionLC status was the significant risk factor of development of HCC during NA therapy. However, none of the patients who showed HBsAg seroclearance developed HCC. The ultimate goal of therapy for reduced risk of HCC may be HBsAg seroclearance.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据